Enhertu May Further Improve Survival Versus Xeloda Regimens in HER2-Positive Breast Cancer
December 24th 2022Recent study results showed that patients with advanced HER2-positive breast cancer lived longer without disease progression when treated with Enhertu compared to when treated with Xeloda.
Read More
Keytruda/Chemo Combo Is ‘Great News’ for Patients With TNBC, ‘But We Need Much More’
January 6th 2022An expert discusses improvements in survival outcomes for patients with triple-negative breast cancer who received Keytruda plus chemotherapy — now considered the standard of care — but urges that more researched is always needed for this patient population.
Read More
Pre-Surgical Keytruda Provides Promising Advancement in TNBC Treatment
December 20th 2021Findings from a clinical trial showed that adding Keytruda to neoadjuvant chemotherapy in patients with triple-negative breast cancer significantly improved outcomes and was overall safe and tolerable for patients.
Read More
Lynparza After Chemo May Not Greatly Impact Quality of Life in High-Risk Early Breast Cancer Subset
December 11th 2021Although patients treated with Lynparza after chemotherapy may experience side effects such as fatigue and nausea/vomiting, these symptoms resolved after treatment was completed in patients with high-risk early breast cancer.
Read More
Experimental Drug Plus Chemo Boosts Survival in HER2-Positive Metastatic Breast Cancer
December 10th 2021The use of pyrotinib — an experimental drug — plus the chemotherapy capecitabine extended survival compared with Tykerb and capecitabine among patients with pretreated HER2-positive metastatic breast cancer.
Read More
Immunotherapy Before Surgery May ‘Increase the Chances’ Patients Are Cured of TNBC
December 9th 2021Clinical trial results show that adding Keytruda to chemotherapy prior to surgery for triple-negative breast cancer can improve outcomes and hopefully “increase the chances for patients to be cured,” according to an expert.
Read More
Study Confirms Adding Ibrance to Endocrine Therapy May Not Improve Outcomes in Early Breast Cancer
December 8th 2021The addition of Ibrance to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, according to final results of the phase 3 PALLAS trial.
Read More
Novel Drug Has Potential to ‘Become New Standard of Care’ in Advanced, ER-Positive Breast Cancer
December 8th 2021The use of elacestrant, an investigational therapy, elicited a 30% reduction in the risk of disease progression or death compared with standard of care in a group of patients with estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.
Read More
Black Women With Breast Cancer Have a Higher Risk of Developing Lymphedema Than White Women
December 7th 2021Black race is associated with a 3.5-fold increased incidence of lymphedema in women with breast cancer treated with axillary lymph node dissection and radiotherapy, according to recent data.
Read More
Keytruda and Chemotherapy Combination Broadens Number of Treatable Patients with TNBC
January 8th 2021In an interview with CURE®, lead study investigator of the Keynote 355 trial, Dr. Hope S Rugo, discusses the results of the study that led to the FDA approval of the combination therapy and what further data means for certain patients with metastatic triple-negative breast cancer.
Read More
Tesetaxel with Reduced Dose of Xeloda Improves Progression-Free Survival in Breast Cancer
December 12th 2020Tesetaxel, a novel agent, with Xeloda contributed to a median progression-free survival of 9.8 months, compared with 6.9 months with Xeloda alone, in patients with metastatic breast cancer.
Read More
Chemotherapy With Endocrine Therapy Shows Clinical Benefit With Improved Survival in Breast Cancer
December 12th 2020Premenopausal women with HR-positive, HER2-negative, lymph node-positive breast cancer and a risk for recurrence experienced benefits with chemotherapy plus endocrine therapy, with improvements in five-year invasive disease-free and overall survival.
Read More